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Abstract The title compound, C23H38N2O2, is the satu-
rated form of a modified steroid derivative Finasteride,
containing a d-lactamide ring, fused to successive cyclo-
hexane and cyclopentane rings which contain a tert-
butylamide residue. It crystallizes in the monoclinic space
group C2 with unit cell parameters a = 9.99450(10),
b = 7.67870(10), c = 28.4954(3), A˚, b = 93.8706(10),
Z = 4. Crystal packing effects are influenced by intermo-
lecular hydrogen bond interactions dominated by an
acceptor OH–(C, N) four-center hydrogen bond interac-
tion around the keto oxygen atom from the d-lactamide
ring in the asymmetric unit. Intramolecular three-center C–
HO hydrogen bonds around the tert-butylamide oxygen
atom appear to have little effect on crystal packing. A
comparison of the geometric parameters of the asymmetric
unit (a 5a isomer) is made and with a solvated analog
compound (a 5b isomer) and some solvated Finasteride
compounds which differ only in the unsaturation of the
C1=C2 bond in the d-lactamide ring. The dihedral angle
between the mean planes of the fused d-lactamide and
cyclohexane rings is 2.5(8) which differs significantly
from the 74.8(8) and 76.1(9) values observed in the sol-
vated analog compound and with its geometry optimized
(MOPAC) computed structure, respectively.
Keywords Androstone  Carboxamide  Finasteride 
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bond
Introduction
The title compound, C23H38O2N2 (I), (Fig. 1) is the satu-
rated form [C(1)–C(2) versus C(1)=C(2)] of the drug
Finasteride (17b-(N-tert-butyl-carbamoyl)-4-aza-5a-and-
rost-1-en-3-one), (II), (Fig. 2) a modified steroid derivative
with two peptide groups (the ring A contains a lactam
group and the tert-butylamide residue is the substituent at
C17). These two groups have generally affected the
strength and pattern of intermolecular contacts between
neighboring molecules in the solid state. Finasteride is a
synthetic 4-azasteroid compound, which is a 5-a-reductase
inhibitor that interferes with the effects of certain male
hormones (androgens) on the prostate [1]. It was originally
used to treat enlarged prostate glands (benign prostatic
hyperplasia) by the US PDF [2]. Finasteride was approved
initially in 1992 as Proscar, a treatment for prostate
enlargement, whereby the sponsor had studied a 1 mg
sample of Finasteride and demonstrated hair growth in
male pattern hair loss [3]. It is used in the prevention of
prostate cancer [4]. The synthesis of the 17-aza isomer
of Finasteride is described with the side chain amide group
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of the compound existing in the Z configuration as the
structure is similar to one of the two favored conformations
of Finasteride. Also, a series of 4,17-diazasteroids has been
assayed against the isoenzymes of human 5a-reductase [5].
The existence of two Finasteride polymorphs was first
reported dependent upon the solvent used for crystalliza-
tion and the mode of crystal treatment, but structural details
were not discussed [6]. Recent studies of related structures
have included a vinyl fluoride mimic of the ‘intermediate’
enol form of Finasteride in the 5a-reductase transformation
and was reported as the synthesis and in vitro activity of
(N-10,10-dimethylethyl)-3-haloandrost-3,5-diene-17b-car-
boxamides [7]. The structures of related compounds of
Finasteride [8], include N-tert-butyl-3-oxo-4-aza-5b,17b-
androstane-17-carboxamide methanol solvate [a Finaste-
ride impurity and nearly identical to the title compound,
(I)] [9], 17-oxo-5a-androstane-3a,4b-diyl diacetate [10]
and 17-oxo-5b-androstane-3a,4b-diyl diacetate [10]. Most
recently a structural study of Finasteride solvate solid
forms has revealed three new crystal structures [11] that are
isomorphous with the ethyl acetate solvate reported earlier
[12]. In view of the importance of title compound, the
crystal structure of an unsolvated C23H38N2O2, (I), is
reported here.
Experimental
3-Oxo-4-aza-5-alpha-androstone-17-b tert-butyl carbox-
amide (I) (a 5a-isomer) was obtained as gift samples from
INTERMED LABS PVT LTD., Bangalore, India. X-ray
quality crystals were grown from methanol by slow evap-
oration of the solvent. The melting range was found to be
522–525 K.
Structure Determination and Refinement
X-ray data for (I) was collected with an Oxford Diffraction
Gemini R CCD area detector using CrysAlisPro software
and graphite-monochromated Cu-Ka (k = 1.54184 A˚) at
200(2) K. The structure was solved by direct methods
using SHELXS97 [13] and all of the non-hydrogen atoms
were refined anisotropically by full-matrix least-squares on
F2 using SHELXL97 [13]. The hydrogen atoms were
placed in their calculated positions and included in the
refinement using the riding model. An absorption correc-
tion was performed using CrysAlis RED and all
calculations were performed using SHELXTL [14]. Addi-
tional bond and geometry calculations were performed
using the software PLATON [15]. Crystal and experi-
mental data for (I) are listed in Table 1. A scheme for the
molecular structure of (I) is shown in Fig. 1. Bond lengths
and bond angles are within expected ranges, Table 2 [16].
Results and Discussion
The title compound, C23H38N2O2, (I), is the saturated form
[at C(1)–C(2)] of a modified steroid derivative called
Finasteride containing a d-lactamide ring (A), fused to
successive cyclohexane (B & C) and cyclopentane (D)
rings containing a tert-butylamide residue at C(16) [17]
(Fig. 3). All of the C–C bonds in the molecule are single
bonds with angles close to normal tetrahedral angles
(Table 2). Because the methyl groups at carbon 4 and 12
are anti to the hydrogen atom at carbon 5 in (I) and syn in
(II), only a limited comparison of bond lengths and angles
involving these groups can be effectively made in these
regions. However, when the bonds and angles of a sol-
vated, 5b-isomer, analog, (II), [9] is compared to the title
compound, (I), a 5a-isomer, some similarities are observed
(Fig. 2). In (I), the somewhat long C(4)–C(9) [=1.5573(19)
A˚] and C(8)–C(9) [=1.546(2) A˚] bonds are affected by
crowding between the methyl groups at C(4) and C(8)
where the separation between H(8A) and H(17C) is only
2.07(7) A˚. The C(1)–O(1) bond (=1.235(2) A˚) is slightly
longer than the C(19)–O(2) bond (=1.222(2) A˚) which is
most likely due to effects from the acceptor OH–(C, N)
inter and intra-molecular four-center hydrogen bond
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Fig. 1 Chemical structure of the title compound, C23H38N2O2, (I). The
methyl groups at C(4) and C(12) are anti to the hydrogen atom at C(5)
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Fig. 2 Chemical structure of Finastride, C23H36N2O2 (II). The
methyl groups at C(4) and C(12) are syn to the hydrogen atom at C(5)
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interactions that exist for O(1) (O(1)H(2A)–C(2),
O(1)H(17B)–C(17), O(1)H(1A)–N(1) and O(1)
H(1A)–N(1), respectively). Details of these hydrogen
bonds are given in Table 3. Bond lengths and bond angles
of (I) show a high degree of similarity with those for the
5b-isomer, methanol solvate form, of the molecule isolated
during impurity profiling of Finasteride [9] as shown in
Table 2 with a comparison of selected geometric
parameters. In this molecule, the C(1)–O(1) bond
(=1.219(8) A˚) is slightly shorter than the C(19)–O(2) bond
(=1.225(7) A˚). The only major difference in angles
between these two molecules (I and II) is observed in the
N(1)–C(5)–C(6)–C(7) torsion angle which at 72.4(6) (II)
is significantly changed from that observed for (I)
(=-173.46(14)) which can be related to the difference in
anti versus syn location of the methyl group at C(4) versus
the hydrogen atom at C(5). This also appears to be influ-
enced by one of the four-center hydrogen bonds
[O(1)H(1A)–N(1)] around oxygen atom (O1) in the
asymmetric unit in (I). In (II) this interaction includes a
Table 1 Crystal and experimental data for (I)
(I)
CCDC deposit No. 701192
Formula C23H38N2O2
Formula weight 374.55
Crystal color, habit Colorless, plate
Crystal size (mm) 0.55 9 0.47 9 0.18
Crystal system Monoclinic
Space group, Z C2, 4
Temperature (K) 200(2)
a (A˚) 9.99450(10)
b (A˚) 7.67870(10)
c (A˚) 28.4954(3)
b () 93.8706(10)
Volume, A˚3 2181.88(4)
F(000) 824
Absorption coef (mm-1) 0.559
Dcalc (Mg m
-3) 1.140
No. of reflections [I [ 2r(I)] 3332
2hmax () with Cu Ka 147.34
R, Rw [I [ 2r(I)] 0.0418, 0.1140
(Dq)max (e A˚
-3) 0.276
(Dq)min (e A˚
-3) -0.220
GOF on F2 1.069
Absolute structure parameter 0.6(3)
Measurement GEMINI (Oxford Diffraction, 2007)
Program system CrysAlisPro
Structure determination SHELXS97
Refinement Full-matrix least-squares
on F2 (SHELXL97)
Table 2 Selected geometric parameters for (I) (A˚, )
O(1)–C(1) 1.235(2) [1.219(8)]* O(2)–C(19) 1.222(2) [1.225(7)]*
C(1)–N(1) 1.337(2) [1.328(7)]* C(19)–N(2) 1.350(3) [1.337(7)]*
O(1)–C(1)–N(1) 121.49(17) [120.6(6)]* O(2)–C(19)–N(2) 123.58(17) [122.5(6)]*
N(1)–C(5)–C(6) 110.47(14) [108.9(5)]* C(3)–C(4)–C(9) 111.47(12) [111.3(4)]*
C(11)–C(12)–C(16) 115.84(14) [115.9(4)]* C(8)–C(13)–C(14) 119.22(14) [119.6(4)]*
O(1)–C(1)–N(1)–C(5) -172.34(16) [-175.3(5)]* N(1)–C(5)–C(6)–C(7) -173.46(14) [72.4(6)]*
O(2)–C(19)–N(2)–C(20) 0.5(3) [2(1)]* O(2)–C(19)–C(16)–C(15) 27.2(3) [-25.4(9)]*
C(7)–C(8)–C(13)–C(14) 54.7(2) [-59.5(6)]* C(11)–C(12)–C(16)–C(19) -80.43(19) [81.6(6)]*
* Comparison to [9], (A˚, )
Fig. 3 ORTEP drawings of (I) showing the atom numbering scheme
of the asymmetric unit and 50% probability displacement ellipsoids of
non-H atoms
Table 3 Hydrogen bonds for (I) (A˚ and )
D–HA d(D–H) d(HA) d(DA) \(DHA)
N(1)–H(1A)O(1)#1 0.88 2.12 2.909(2) 148.5
C(2)–H(2A)O(1)#2 0.99 2.62 3.379(2) 133.1
C(17)–H(17B)O(1)#3 0.98 2.64 3.442(2) 138.7
N(1)–H(1A)O(1) 0.88 2.12 2.908(6) 127.1
C(15)–H(15B)O(2) 0.98 2.43 2.869(8) 106
C(22)–H(22B)O(2) 0.98 2.53 3.117(6) 118
C(23)–H(23A)O(2) 0.98 2.47 3.071(5) 119
Symmetry transformations used to generate equivalent atoms: #1,
–x ? 3/2, y - 1/2, -z ? 2; #2, –x ? 3/2, y ? 1/2, -z?2; #3,
–x ? 1, y, -z ? 2
460 J Chem Crystallogr (2009) 39:458–465
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Table 4 Comparison of fused
ring shapes [18] for (I), [9] and
related Finasteride analogs
A B C D
C23H38N2O2 (I) Q 0.512(0) 0.588(1) 0.578(4)
h 136.4(5) 7.3(4) 176.1(1)
/ 43.586(1) 17.571(3) 93.042(7) 12.610(6)
Sofa Chair Chair Envelope
Details for solvated analog
C23H38N2O2.C1H4O1 [9] (CSD: BEQKEN) Q 0.485(4) 0.558(8) 0.570(7)
h 123.7(9) 176.6(0) 6.4(2)
/ 42.302(9) 77.716(5) 250.903(3) 191.985(5)
Sofa Chair Chair Envelope
Details for related Finasteride analogs
C23H36N2O2 [19] (CSD: WOLXOK02) Q 0.507(3) 0.590(3) 0.578(3)
h 63.2(4) 0.0(3) 7.3(3)
/ 277.3(4) 284(9) 269(3) 191.9(5)
Envelope Chair Chair Envelope
C23H36N2O2 [19] (CSD: WOLXOK03)
Molecule A Q 0.496(6) 0.624(6) 0.574(8)
h 64.2(7) 4.6(6) 4.6(8)
/ 279.3(8) 314(9) 289(8) 185.3(8)
Envelope Chair Chair Envelope
Molecule B Q 0.506(6) 0.626(7) 0.588(6)
h 61.5(7) 5.5(6) 5.6(6)
/ 277.9(8) 342(7) 289(6) 187.3(8)
Envelope Chair Chair Envelope
Details for Bis (Finasteride) monosolvate monohydrates [11]
2(C23H36N2O2), (H2O1) (C4H8O2) (Dioxane solvate hydrate, 11; CCDC: #638162)
Molecule A Q 0.484(4) 0.6000(5) 0.579(4)
h 117.6(3) 174.0(4) 177.8(4)
/ 100.2(3) 125(3) 68(6) 11.3(5)
Envelope Chair Chair Envelope
Molecule B Q 0.480(4) 0.590(4) 0.580(4)
h 118.5(5) 173.4(4) 176.9(4)
/ 98.2(3) 127(3) 95(6) 8.7(6)
Envelope Chair Chair Envelope
2(C23H36N2O2), (H2O1) (C3H8O1) (IPA solvate hydrate, 11; CCDC: #638163)
Molecule A Q 0.486(4) 0.597(4) 0.582(4)
h 117.9(5) 173.4(4) 175.3(4)
/ 99.9(5) 123(3) 62(5) 10.3(5)
Envelope Chair Chair Envelope
Molecule B Q 0.494(4) 0.594(4) 0.577(4)
h 117.3(5) 173.3(4) 175.5(4)
/ 97.3(6) 124(3) 81(5) 9.8(6)
Envelope Chair Chair Envelope
2(C23H36N2O2), (H2O1) (C4H8O2) (THF solvate hydrate, 11; CCDC: #638164)
Molecule A Q 0.483(5) 0.596(5) 0.596(5)
h 116.2(6) 174.1(5) 174.1(3)
/ 98.0(7) 122(5) 122(5) 10.5(7)
Envelope Chair Chair Envelope
Molecule B Q 0.482(5) 0.589(5) 0.56(85)
h 116.8(7) 174.5(5) 176.1(5)
/ 98.2(7) 126(5) 100(8) 9.2(8)
Envelope Chair Chair Envelope
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N(1)–H(1)O(3) hydrogen bond interaction between N(1)
from the the d-lactamide ring and solvent oxygen atom
O(3) and the N(2)–H(29)O(1) hydrogen bond interaction
between the keto oxygen atom [O(1)] in the d-lactamide
ring with the tert-butylamide nitrogen atom [N(2)] from a
nearby C23H38N2O2 molecule [x – 1/2, -y ? 3/2, -z ?
2]. While small differences are observed for C(1)–N(1)
(=1.328(7) A˚) [9] versus (=1.337(2) A˚) (I) and C(19)–N(2)
(=1.337(7) A˚) [9] versus (=1.350(3) A˚) (I) bond lengths.,
no conclusions can be made here since data collection in
each venue was not made at comparable temperatures and
appropriate corrections were not considered. It is interest-
ing to note that in (I), no intermolecular interactions are
observed with the tert-butylamide nitrogen atom, N(2).
Even though the N(2)–C(19)–O(2) group forms a dialkyl
trans secondary amide with considerable steric projection,
it displays only a series of weak C–HO intramolecular
hydrogen bonds that appears to have little effect on crystal
packing (Table 2). In contrast, the cis lactamide group
[N(1)–C(1)–O(1)] has both donors and acceptors and
intermolecular contacts which form a hydrogen-bonded
chain between the molecules around the twofold screw axis
along the crystallographic (unique) b axis of type C11(4)
and therefore does influence crystal packing.
The two trans fused cyclohexane rings (B & C) in (I)
form a slightly distorted chair–chair (or double-chair)
conformation and is confirmed by the ring torsion angles
and the puckering parameters h [18] which are 7.3(4)
[C(4)–C(9)] and 176.1(1) [C(8)–C(13)] for rings B and C,
respectively (for an ideal chair h = 0 or 180-0). These
values are in general agreement with reported values for
the identical, saturated, solvated molecule in [9] (CSD
refcode BEQKEN [9]) and closely related unsaturated
Finasteride structures (CSD refcodes WOLXOK02 [19]
and WOLXOK03 [19]; Table 4). The methyl groups in (I)
at C(4) and C(12), the heaviest substituents in the cyclo-
hexane rings occupy axial positions. In WOLXOK02,
WOLXOK03, and in each of the three related Bis(Finas-
teride) monosolvate monohydrate compounds (#638162,
#638163 and #638614) these methyl groups are anti to the
hydrogen atom at C(5) making comparisons to them more
relevant (Tables 4, 5, 6).
The dihedral angle between the mean planes of the mean
planes of the fused rings (A & B; B & C; C & D) in (I) is
2.5(8), 4.4(5) and 7.1(0) while the dihedral angle
between the mean plane of ring D and the best plane of the
keto group [N(2)–C(19)–O(2)–C(16)] is 54.8(7), respec-
tively, Table 5. These values are somewhat similar to those
Table 5 Comparison of dihedral angles between fused rings and ring D versus C–C(=O)–N (keto group) for (I) (), [9], [19] and [21]
A & B B & C C & D D & keto
(C23H38N2O2) (I) 2.5(8) 4.4(5) 7.1(1) 54.8(7)
Details for solvated analog
(C23H38N2O2), (C1H4O1) [9] (CSD: BEQKEN) 74.8(8) 4.0(1) 5.9(1) 52.9(4)
C23H38N2O2, (C1H4O1) [9] (MOPAC-AM1) 76.1(9) 5.4(1) 9.5(7) 45.8(3)
Details for related Finasteride analogs
(C23H36N2O2) [19] (CSD: WOLXOK02) 9.9(1) 2.5(8) 4.6(9) 56.0(8)
(C23H36N2O2) [19] (CSD: WOLXOK03)
Molecule A 9.5(4) 3.7(2) 6.4(1) 56.3(0)
Molecule B 8.7(3) 1.5(3) 5.7(8) 55.4(5)
(C23H36N2O2), C2H4O2 [21] (CSD: WOLXEA) 6.1(6) 5.5(2) 8.7(3) 55.4(6)
2(C23H36N2O2), (C4H8O2), (H2O1) [20] (CSD: WOLXIE)
Molecule A 5.8(1) 3.9(1) 9.9(6) 48.6(5)
Molecule B 5.5(3) 5.4(6) 8.7(5) 53.9(0)
Details for Bis (Finasteride) monosolvate monohydrates [11]
2(C23H36N2O2), (H2O1) (C4H8O2) (Dioxane solvate hydrate, 11; CCDC: #638162)
Molecule A 9.0(4) 5.4(9) 6.0(9) 54.8(1)
Molecule B 8.4(1) 5.0(9) 6.1(2) 46.8(9)
2(C23H36N2O2), (H2O1) (C3H8O1) (IPA solvate hydrate, 11; CCDC: #638163)
Molecule A 9.1(2) 4.6(7) 5.7(3) 55.3(8)
Molecule B 7.8(1) 4.3(6) 5.5(4) 49.4(1)
2(C23H36N2O2), (H2O1) (C4H8O2) (THF solvate hydrate, 11; CCDC: #638164)
Molecule A 8.6(7) 5.5(4) 5.0(6) 54.5(4)
Molecule B 7.4(5) 4.8(7) 5.3(4) 46.3(2)
462 J Chem Crystallogr (2009) 39:458–465
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in [9] with the exception of (A & B) which has a value of
74.8(8) by comparison. This dramatic difference in the
dihedral angle between (A & B) is also most likely due to
the close intermolecular interaction of the solvent molecule
in [9] with the d-lactamide ring as well as the difference
between the anti and syn relationships of the two methyl
groups at C4 and C12 with the hydrogen aton at C(5). In
addition, in (II), there is a significant influence of the N(1)–
H(1)O(3) hydrogen bond interaction between N(1) from
the the d-lactamide ring and solvent oxygen atom O(3) and
the N(2)–H(29)O(1) hydrogen bond interaction between
the keto oxygen atom [O(1)] in the d-lactamide ring
with the tert-butylamide nitrogen atom, N(2), from a
nearby C23H38N2O2 molecule [x-1/2, -y ? 3/2, -z ? 2].
MOPAC calculations (AM1 approximation together with
the Hartree-Fock closed-shell restricted wave function was
used and minimizations were teminnated at an r.m.s. gra-
dient of less than 0.01 kJ mol-1 A˚-1) [20] on the solvated
molecule [9] support this observation with a calculated (A
& B) separation of 76.1(9).
A comparison of the dihedral angles between the mean
planes of the fused rings (A & B; B & C; C & D) as well as
Table 6 Comparison of selected geometric parameters for (I) (A˚, ), [9], [19] and [21]
(C23H38N2O2) [I] C1–C2 1.530(9) C1–O1 1.234(8)
C19–O2 1.222(4)
Details for solvated analog
(C23H38N2O2), (C1H4O1) [9] (CSD: BEQKEN) C1–C2 1.495(2) C1–O1 1.218(2)
C19–O2 1.225(4)
(C23H38N2O2), (C1H4O1) [9] (MOPAC-AM1) C1–C2 1.49(5) C1–O1 1.24(4)
C19–O2 1.24(8)
Details for related Finasteride analogs
(C23H36N2O2) [19] (CSD: WOLXOK02) C1–C2 1.330(4) C3–O1 1.230(3)
C19–O2 1.219(4)
(C23H36N2O2) [19] (CSD: WOLXOK03)
Molecule A C1–C2 1.350(8) C3–O1 1.210(7)
C19–O2 1.214(7)
Molecule B C24–C25 1.365(8) C3–O1 1.242(7)
C42–O4 1.232(7)
(C23H38N2O2), C2H4O2 [21] (CSD: WOLXEA) C1–C2 1.334(6) C3–O1 1.250(5)
C19–O2 1.217(5)
2(C23H38N2O2), (C4H8O2), (H2O1) [20] (CSD: WOLXIE)
Molecule A C1–C2 1.354(16) C3–O1 1.280(16)
C19–O2 1.181(19)
Molecule B C24–C25 1.326(16) C3–O1 1.204(16)
C42–O4 1.260(17)
Details for Bis(Finasteride) monosolvate monohydrates [11]
2(C23H36N2O2), (H2O1) (C4H8O2) (Dioxane solvate hydrate, 11; CCDC: #638162)
Molecule A C1–C2 1.337(5) C3–O3 1.248(4)
C20–O20 1.227(5)
Molecule B C26–C27 1.320(5) C28–O28 1.246(4)
C45–O45 1.206(8)
2(C23H36N2O2), (H2O1) (C3H8O1) (IPA solvate hydrate, 11; CCDC: #638163)
Molecule A C1–C2 1.345(5) C3–O3 1.262(4)
C20–O20 1.234(5)
Molecule B C26–C27 1.331(5) C28–O28 1.245(7)
C45–O45 1.234(7)
2(C23H36N2O2), (H2O1) (C4H8O2) (THF solvate hydrate, 11; CCDC: #638164)
Molecule A C1–C2 1.341(7) C3–O3 1.258(6)
C20–O20 1.237(7)
Molecule B C26–C27 1.334(7) C28–O28 1.240(6)
C45–O45 1.211(9)
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between the mean plane of ring D and the N–(C=O)–C keto
group with a few solvated Finasteride analog molecules
[19, 21, 11] indicate that the solvents present in the crystal
packing for these molecules do not alter the angles between
these rings significantly from that seen in (I) (Table 5).
This is most likely because of greater intermolecular dis-
tances between these species ([4 A˚) as observed in the unit
cell for a typical hydrogen bond interaction.
The C(1)–C(2) bond length in (I) (=1.530(9) A˚) being
slightly shorter that a normal C–C single bond reflects the
effects of one of the four-center intermolecular hydrogen
bond interactions [C(2)–H(2A)O(1)] from the cyclopen-
tane D ring (C(2)–H(2A)) and a keto group [O(1)–C(1)]
of a nearby molecule (-x ? 3/2, y ? 1/2, -z ? 2). In
comparison to that observed in [9] involving solvent inter-
action in this region of the molecule, whereby the C(1)–
C(2) bond length becomes 1.495(2) A˚, it is clear that factors
such as nearby solvent attraction [N(1)–H(1)O(3)] from
the d-lactamide ring as well as intermolecular hydrogen
bond interactions [N(2)–H(29)O(1)] from the tert-butyl-
amide residue (N(2)–H(29)) and nearby symmetry related
keto oxygen atom [O(1)] (x-1/2, -y ? 3/2, -z ? 2)
affects the hybridization of the C(1) and C(2) atoms giving
them some partial double bond character (Table 6). A
MOPAC calculation which included the solvent molecule
gives the C(1)–C(2) bond length of 1.49(5) A˚. The varied
differences in bond lengths for the unsaturated [C(1)=C(2)]
bond character observed for related Finasteride analogs
provides support for our observations of the saturated single
bond character of these molecules indicating that the
influence of intermolecular hydrogen bond interactions and
various packing effects do in fact play a role in the shapes of
these types of structurally related molecules.
Differences in bond lengths and geometric parameters of
the keto groups from the d-lactamide ring, C(1)=O(1)
(=1.235(2) A˚), as well as from the tert-butylamide residue,
C(19)=O(2) (=1.222(2) A˚) in (I) are observed and again can
be related to intermolecular hydrogen bond interactions and
packing effects somewhat similar to those described above
(Table 6). The four-center intermolecular hydrogen bond
around O(1) and a three-center intramolecular hydrogen
bond around O(2) (C(15)–H(15B)O(2), C(22)–H(22B)
O(2), C(23)–H(23A)O(2) (see Table 3 for details) provide
support to the influence of nearby atoms on these two sep-
arate keto bond lengths. In [9], this bond length is
1.218(2) A˚ with the N(2)–H(29)O(1) intermolecular
interaction providing the major influence on its length.
The molecules in (I) align themselves in a three-
dimensional network in chains diagonal to the bc plane and
along the (011) axis of the unit cell. A view of the N(1)–
H(1A)O(1) component of the four-center hydrogen bond
can be seen along the c axis of the unit cell (Fig. 4). A view
of two components of the four-centered hydrogen bond
(O(1)H(1A)–N(1) and O(1)H(2A)C(2) hydrogen)
can be seen when viewed down the a axis (Fig. 5). The
C(17)–H(17B)O(1) intermolecular hydrogen bond can be
seen when viewed down the b axis (Fig. 6).
In conclusion, the geometrical parameters of title com-
pound, C23H38N2O2, (I), containing a d-lactamide ring (A),
fused to successive cyclohexane (B & C) and cyclopentane
(D) rings containing a tert-butylamide residue at C(17) [17]
shows much similarity to an analog compound [9] as well
Fig. 4 The molecular packing for (I) viewed down the c axis. Dashed
lines indicate intermolecular N(1)–H(1A)O(1) hydrogen bonds
Fig. 5 The molecular packing for (I) viewed down the a axis. Dashed
lines indicate intermolecular bifurcated acceptor O(1)H(1A)–N(1)
and O(1)H(2A)–C(2) hydrogen bonds
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as to a number of related unsaturated, solvated derivatives
of the compound, Finasteride. Crystal packing effects are
influenced by intermolecular hydrogen bond interactions
which include acceptor OH–(C, N) intermolecular four-
center hydrogen bond interactions around the keto oxygen
atom from the d-lactamide ring as well as an intramolec-
ular three-center C–HO hydrogen bond around the tert-
butylamide oxygen atom in the asymmetric unit. It is
apparent that the introduction of solvation in addition to
observed intermolecular hydrogen bonding interactions
play a significant role in the geometric structure and
packing effects in title compound as well as in its closely
related analogs.
Supporting Information Available
X-ray crystallographic files, in Cif format, for the structure
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from the Director, CCDC, 12 Union Road, Cambridge,
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